Focus Area: Diagnostics Accelerator
60 Results for 'Diagnostics Accelerator'
- Technologies (10)
- Collaborations (4)
- Team (0)
- News (19)
- Pages (0)
- Multimedia (27)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 10
-
Extracellular Vesicles for Biomarker Detection
A non-invasive method to identify biomarkers of disease across cell types and develop diagnostics and monitoring systems. -
Instrument-Free Molecular Diagnostics
A synthetic biology-based molecular diagnostics platform that enables the creation of low-cost, highly accurate tests for non-clinical settings. -
Paper-Based Diagnostics
With the imminent threat of new pandemics and frequent disease outbreaks exemplified by the recent Ebola and Zika epidemics, there is a growing need for low-cost, easily deployable and simple-to-use diagnostic tools. The Wyss Institute has developed paper-based synthetic gene networks as a next generation diagnostic technology for use in global healthcare crises and patient... -
FcMBL: Broad-Spectrum Pathogen Capture for Infectious Disease Diagnosis and Therapy
The Problem Infectious diseases have plagued humanity for millennia, and the pathogens that infect and sicken humans are constantly evolving. Severe infections can cause sepsis, a life-threatening condition in which a patient’s immune system overreacts to the infection. The body starts to attack itself, which can lead to tissue damage, organ failure, and death. Sepsis... -
abbieSense: Anaphylaxis Diagnostic
The molecule histamine plays a primary role in the anaphylaxis reaction, which is a major cause of illness and death in people with severe allergies. Histamine is a very small molecule composed of only seventeen atoms, making it a challenging target to detect. To date, no diagnostic test exists that can measure histamine levels accurately... -
Toehold Switches for Synthetic Biology
The burgeoning field of synthetic biology is designing artificial gene circuits that recognize molecules in their environment and respond by regulating genes with desired activities. In the future, such capabilities could allow the engineering of cells as diagnostic or therapeutic devices, factories for the production of clinically or industrially coveted molecules, and as specialized devices...
Collaborations 4
-
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration. -
Wyss DxA Industrial Participant Program
As the industry-facing component of the Wyss Diagnostics Accelerator, the Industrial Participant Program is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem that seeks to compress the timeframe for bringing new, high-impact, diagnostic technologies to market. -
Wyss Diagnostics Accelerator (DxA)
An initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs.
News 19
Multimedia 27
-
Video/AnimationHow can we get diagnostics to patients faster?The Wyss Diagnostics Accelerator (DxA) is an initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs. Credit: Wyss Institute at Harvard University -
Video/AnimationReimagine the World – Volume 2 – Diagnostics AcceleratorTwo clinicians collaborating with the Wyss Diagnostics Accelerator (DxA), Lise Johnson and Craig Hersh, as well as two members of the Wyss DxA Industrial Partnership Program, Nell Meosky Luo and Andy Levin, share how they would Reimagine the World and the personal stories that fuel their passion for the work they are doing. Credit: Wyss... -
Video/AnimationWyss Diagnostics Accelerator – The Industrial Participant ProgramThe Industrial Participant Program (IPP) is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem, driven by the Wyss Diagnostics Accelerator (DxA). Members of the IPP share the common goal of fast-tracking diagnostic technologies to meet unmet, critical needs. Credit: Wyss Institute at Harvard University -
Video/AnimationReimagining Health Equity: Wyss Diagnostics AcceleratorWith the Wyss Diagnostics Accelerator (DxA), we’re reimagining health equity by accelerating the development and deployment of needed diagnostics in all settings, particularly in low-resource settings, by fostering deep collaborations driven by unmet needs. Credit: Wyss Institute at Harvard University -
Video/AnimationReimagining Diagnostics for His Mom: Pawan JollyPawan Jolly is a Senior Staff Scientist leading the Sensors team to help develop better diagnostics for various illnesses and allergies. He also serves as the technology lead for the Wyss Diagnostics Accelerator. In this video, he shares a heartfelt personal story about his mom who suffers from severe allergies and how he would Reimagine... -
Video/Animation2021 Kabiller Prize in Nanoscience and NanomedicineDavid R. Walt, a Wyss Core Faculty member, member of the faculty at Harvard Medical School in the Department of Pathology, and a Howard Hughes Medical Institute Professor, is the winner of the 2021 Kabiller Prize in Nanoscience and Nanomedicine, the world’s largest monetary award for outstanding achievement in the field of nanotechnology and its...